Anticoagulant RNA-Based Therapies For SARS-CoV-2 Related Thrombosis

Originally posted on UBC Research Innovation


UBC Project Lead(s): Christian Kastrup

UBC Collaborators: Pieter Cullis

Funding Body: CIHR Foundation Grant and Bayer Hemophilia Awards Program

Funding Amount: $200,000

COVID-19 Research Area(s): Vaccines & Treatments

SARS-CoV-2 leads to hyper-coagulability of blood and deadly blood clots (thrombosis). The current anticoagulants may not be sufficient, due to the risk of bleeding from these drugs, and there is a need for alternative anticoagulants. In particular, agents that enhance clot degradation (fibrinolysis) without inducing bleeding are needed. We have been developing RNA-based agents that enhances fibrinolysis without leading to bleeding.

We have developed siRNA-based agents to modulate coagulation proteins and the proteins involved in clot degradation. Since there is a need for agents that safely enhance the degradation of blood clots, we are testing if several of these siRNA-based agents are effective.

Collaboration opportunities:
Clinical thrombosis, bleeding, hematology, transfusion.